Dr Rob De Rose
Research Fellow
Department of Infectious Diseases
116 Scholarly works
13 Projects
HIGHLIGHTS
2026
Journal article
Targeting rapidly cycling receptors CD2 and CD7 increases nanoparticle delivery to primary CD4 T cells.
DOI: 10.1038/s41467-026-74981-22025
Journal article
Amplifying the Immune Activity of Metal Ions through Metal-Phenolic Complexation
DOI: 10.1021/acsnano.5c018422025
Journal article
Trafficking Glycogen Nanoparticles through Lymph Node Tissues for the Delivery of Small and Large Bioactive Molecules
DOI: 10.1021/acsnano.5c131342024
Journal article
mRNA delivery enabled by metal–organic nanoparticles
DOI: 10.1038/s41467-024-53969-w2024
Research contracts (non-grants)
In Vivo Analysis of Lung Targetting LNP
2022
Research grants (other domestic)
mRNA-based Antiviral Therapeutics for SARS-CoV-2 Using Cas13
2022
Research Grant
mRNA-based Antiviral Therapeutics for SARS-CoV-2 Using Cas13
RECENT SCHOLARLY WORKS
2024
Journal article
A Metal–Phenolic Network-Enabled Nanoadjuvant to Modulate Immune Responses
DOI: 10.1002/smll.2024017762024
Journal article
Metal–Phenolic‐Mediated Assembly of Functional Small Molecules into Nanoparticles: Assembly and Bioapplications
DOI: 10.1002/ange.2023195832024
Journal article
Metal–Phenolic-Mediated Assembly of Functional Small Molecules into Nanoparticles: Assembly and Bioapplications
DOI: 10.1002/anie.2023195832023
Journal article
Supramolecular Polyphenol-DNA Microparticles for In Vivo Adjuvant and Antigen Co-Delivery and Immune Stimulation
DOI: 10.1002/anie.2022149352023
Journal article
Supramolecular Polyphenol‐DNA Microparticles for In Vivo Adjuvant and Antigen Co‐Delivery and Immune Stimulation
DOI: 10.1002/ange.2022149352023
Journal article
Poly(ethylene glycol) Cross-Linked Antibody Nanoparticles for Tunable Biointeractions
DOI: 10.1021/acs.chemmater.3c00323
RECENT PROJECTS
2025
Research grants (other domestic)
Developing CRISPR Cas13 Antiviral Therapeutics for Respiratory Pathogens of Pandemic Potential
2022
Internal Research Grant
mRNA-based Antiviral Therapeutics for SARS-CoV-2 Using Cas13